苦黄注射液预防抗结核药物导致的药物性肝损伤患者疗效研究*

doi:10.3969/j.issn.1672-5069.2024.01.015

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (1): 56-59.doi: 10.3969/j.issn.1672-5069.2024.01.015

苦黄注射液预防抗结核药物导致的药物性肝损伤患者疗效研究^*

任浩, 刘力伟, 施维, 刘波, 吴于青, 吕芹

210003 南京市南京中医药大学附属南京医院/南京市第二医院肝病科(任浩);安徽医学高等专科学校医学技术学院(刘力伟,施维);解放军第901医院感染病科(刘波);江西省胸科医院结核病科(吴于青);北京市丰台区中西医结合医院消化内分泌科(吕芹)

收稿日期:2023-05-26 出版日期:2024-01-10 发布日期:2024-01-04
通讯作者: 吕芹,E-mail:1632166369@qq.com
作者简介:任浩,男,30岁,医学硕士,住院医师。主要从事疑难重症肝病的诊断与治疗学研究。E-mail:292951393@qq.com 共同第一作者:刘力伟,女,35岁,医学博士,副研究员。主要从事肝病免疫治疗学研究。E-mail:18909696181@163.com
基金资助:
^*安徽省教育厅重点自然科学研究基金结核分枝杆菌分子生物学检测技术及耐药性研究项目(编号:KJ2020A0863)

Administration of Kuhuang, a herbal injection compound, in preventing anti-tuberculosis drug-induced liver injury in patients with naïve pulmonary tuberculosis

Ren Hao, Liu Liwei, Shi Wei, et al

Department of Liver Diseases, Second Hospital, Nanjing University of Chinese Traditional Medicine, Nanjing 210003, Jiangsu Province, China

Received:2023-05-26 Online:2024-01-10 Published:2024-01-04

摘要/Abstract

摘要： 目的本研究观察了应用苦黄注射液预防抗结核药物诱发药物性肝损伤(DILI)的作用,以避免不合理的抗痨中断治疗。方法 2022年3月～2022年11月我院收治的97例肺结核患者,被随机分为试验组50例和对照组47例。所有患者均接受标准的2HREZ/4HR抗结核治疗,试验组在此治疗的基础上加用苦黄注射液治疗8周。采用ELISA法检测血清白介素6(IL-6)和肿瘤坏死因子-α(TNF-α),采用放射免疫法检测血清血红素加氧酶( HO-1)和超氧化物歧化酶(SOD)水平。结果在治疗4周末,试验适应性肝损伤和DILI发生率分别为6.0%和2.0%,显著低于对照组的17.0%和8.5%(P＜0.05),在治疗8周末,试验组适应性肝损伤和DILI发生率分别为6.0%和4.0%,显著低于对照组的21.3%和17.0%(P＜0.05);在治疗8周末,试验组血清ALT、AST和TBIL水平分别为(28.4±23.4)U/L、(30.8±18.7)U/L和(12.9±7.3)μmol/L,显著低于对照组【分别为(53.1±33.1)U/L、(52.5±37.7)U/L和(20.1±10.9)μmol/L,P＜0.05】; 试验组血清HO-1和SOD水平分别为(200.3±14.0)U/L和(418.0±18.7)U/L,显著高于对照组【分别为(128.8±21.4)U/L和(318.0±15.1)U/L,P＜0.05】,而血清IL-6和TNF-α水平分别为(11.4±1.9)ng/L和(9.3±1.8)ng/L,显著低于对照组【分别为(17.5±4.0)ng/L和(14.5±3.0)ng/L,P＜0.05】。结论在抗痨开始时应用苦黄能够显著降低DILI的发生,尽可能地维持标准化抗结核治疗,且安全性良好。

关键词: 药物性肝损伤, 肺结核, 抗结核药物, 适应现象, 苦黄, 预防

Abstract: Objective This study was to observe the Kuhuang, a herbal injection compound, in preventing anti-tuberculosis drugs (ATD)-induced liver injury(DILI) for avoiding unreasonable anti-tuberculosis treatment interruption. Methods A total of 97 patients with naïve pulmonary tuberculosis were encountered in our hospital between March 2022 and November 2022, and were randomly divided into control (n=47) and observation (n=50) groups, receiving standardized 2HREZ/4HR anti-tuberculosis therapy, or intravenous injection of Kuhuang compound at base of anti-tuberculosis for 8 weeks. Serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were detected by ELISA, and serum heme oxygenase (HO-1) and superoxide dismutase (SOD) levels were detected by radioimmunoassay. Results At the end of 4 week anti-tuberculosis treatment, the incidences of adaptive liver injury (ALI) and DILI in the observation group were 6.0% and 2.0%, much lower than 17.0% and 8.5%(P＜0.05) in the control, and at the end of 8 week treatment, the incidences of ALI and DILI were 6.0% and 4.0%, much lower than 21.3% and 17.0%(P＜0.05) in the control group; at the end of 8 week treatment, serum ALT, AST and total bilirubin levels in the observation group were (28.4±23.4)U/L, (30.8±18.7)U/L and (12.9±7.3)μmol/L, all significantly lower than [(53.1±33.1)U/L, (52.5±37.7)U/L and (20.1±10.9)μmol/L, respectively, P＜0.05] in the control; serum HO-1 and SOD levels were (200.3±14.0)U/L and (418.0±18.7)U/L, both significantly higher than [(128.8±21.4)U/L and (318.0±15.1)U/L, P＜0.05], while serum IL-6 and TNF-α levels were (11.4±1.9)ng/L and (9.3±1.8)ng/L, both significantly lower than [(17.5±4.0)ng/L and (14.5±3.0)ng/L, respectively, P＜0.05] in the control. Conclusion The administration of Kuhuang injection compound could prevent the occurrence of anti-tuberculosis DILI, and guarantee the standardized anti-tuberculosis treatment completing.

Key words: Drug-induced liver injury, Pulmonary tuberculosis, Antituberculosis medicines, Adaptation phenomenon, Kuhuang injection, herbal medicine, Prevention

任浩, 刘力伟, 施维, 刘波, 吴于青, 吕芹. 苦黄注射液预防抗结核药物导致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 56-59.

Ren Hao, Liu Liwei, Shi Wei, et al. Administration of Kuhuang, a herbal injection compound, in preventing anti-tuberculosis drug-induced liver injury in patients with naïve pulmonary tuberculosis[J]. Journal of Practical Hepatology, 2024, 27(1): 56-59.

参考文献

[1] Wang YS, Zhu WL, Li T, et al. Changes in newly notified cases and control of tuberculosis in China: time-series analysis of surveillance data. Infect Dis Poverty, 2021, 10:1-10.
[2] 杨松, 郭建琼, 严晓峰. 抗结核药物性肝损伤发生机制的研究进展. 中华结核和呼吸杂志, 2019, 42(5):378-381.
[3] 中华医学会消化病学分会肝胆疾病协作组.全国多中心急性药物性肝损伤住院病例调研分析.中华消化杂志,2007,27(7):439-442.
[4] 许建明,蔡轶.药物性肝损伤适应与耐受的认识与困惑. 中华肝脏病杂志,2012,20(3):148-181.
[5] Nagarajan S, Whitaker P. Management of adverse reactions to first-line tuberculosis antibiotics. Curr Opin Allergy Clin Immunol, 2018, 18(4): 333-341.
[6] Huo F, Lu J, Zong Z, et al. Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China. BMC Infect Dis,2019, 19(1):689.
[7] Saukkonen JJ, Cohn DL, Jasmer RM, et al. Antituberculosis therapy subcommittee. an official ATS statement: hepatotoxicity of antitiberculosis therapy. Am J Respir Crit Care Med ,2006, 174(8):935-952.
[8] 中华医学会呼吸系统疾病基层诊疗指南编写专家组. 肺结核基层诊疗指南(2018年). 中华全科医师杂志, 2019, 18(8): 709-717.
[9] 中华医学会结核病学分会. 抗结核药所致药物性肝损伤诊断与处理专家建议. 中华结核和呼吸杂志, 2013, 36(10): 732-736.
[10] Rawat A, Chaturvedi S, Singh AK, et al. Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid. Hum Exp Toxicol, 2018, 37(4):373-389.
[11] Cao J, Mi Y, Shi C, et al. First-line anti-tuberculosis drugs induce hepatotoxicity: a novel mechanism based on a urinary metabolomics platform. Biochem Biophys Res Commun, 2018, 497(2): 485-491.
[12] Elmorsy E, Attalla S M, Fikry E, et al. Adverse effects of antituberculosis drugs on HepG2 cell bioenergetics. Hum Exp Toxicol, 2017, 36(6): 616-625.
[13] Guo H L, Hassan H M, Ding P P, et al. Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2α-ATF4-CHOP pathway. Toxicology, 2017, 378: 65-75.
[14] Zhang W, Chen L, Shen Y, et al. Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERKATF4-CHOP pathway. Toxicol In Vitro, 2016, 36: 186-196.
[15] Usui T, Meng X, Saide K, et al. From the cover: characterization of isoniazid-specific T-cell clones in patients with anti-tuberculosis drug-related liver and skin injury. Toxicol Sci, 2017, 155(2): 420-431.
[16] Garcia-Cortes M, Robles-Diaz M, Stephens C, et al. Drug induced liver injury: an update. Arch Toxicol, 2020, 94(10):3381-3407.
[17] Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci,2010, 118(1):7-18.
[18] Roth RA, Maiuri AR, Ganey PE. Idiosyncratic drug-induced liver injury: is drug-cytokine interaction the linchpin? J Pharmacol Exp Ther,2017, 360(2):461-470.
[19] Wink S, Hiemstra SW, Huppelschoten S, et al. Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury. Arch Toxicol,2018, 92(5):1797-1814.
[20] Kramar B, Pirc Marolt T, Monsalve M, et al. Antipsychotic drug aripiprazole protects liver cells from oxidative stress. Int J Mol Sci,2022, 23(15):8292.

苦黄注射液预防抗结核药物导致的药物性肝损伤患者疗效研究^*

Administration of Kuhuang, a herbal injection compound, in preventing anti-tuberculosis drug-induced liver injury in patients with naïve pulmonary tuberculosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郎平, 崔闪闪, 赵艳. 药物性肝损伤患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 382-385.
[2]	梁丹丹, 江建宁, 黄锦妮, 龙诗雨, 董国珍, 苏曼, 李继娇, 滕春玲, 张萍, 苏明华. 219例药物性肝损伤患者临床特征和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 210-213.
[3]	张天祺, 王敏, 杨娜, 朱怀军. 应用替加环素治疗重症感染患者DILI发生及其影响因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 214-217.
[4]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[5]	李玲, 何小琪, 高勇, 方春田, 盛天驰, 王燕, 郑红梅. 孕期药物性肝损伤患者血清miR-21、Nrf2和HO-1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 662-665.
[6]	莫俊俏, 林景, 羊莉. 水飞蓟宾胶囊联合多烯磷脂酰胆碱治疗抗结核药物所致药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 666-669.
[7]	裴素娟, 郭锦辉, 魏晓霞. 综合医院住院患者药物性肝损伤发生致病药物及影响肝损伤严重程度的因素分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 670-673.
[8]	桂芬芬, 周杰斌. MicroRNAs作为药物性肝损伤生物标记物研究进展[J]. 实用肝脏病杂志, 2023, 26(5): 761-764.
[9]	符馨尹, 林小茹, 郑秀芬, 刘小双. 药物诱导性自身免疫性肝炎与药物性肝损伤和自身免疫性肝炎患者临床特征比较研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 512-515.
[10]	唐新华, 唐慧京, 黄成军, 李观. 恩替卡韦治疗血清HBeAg阳性高病毒载量乙型肝炎病毒携带者合并肺结核患者预防抗痨治疗引起的药物性肝损伤效果研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 516-519.
[11]	王俊红, 戴玲, 陈国斌, 杨路平, 周晶. 还原型谷胱甘肽、甘草酸二铵和复方甘草酸苷治疗抗结核药物所致药物性肝损伤患者成本-效益分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 380-383.
[12]	杨开宁, 王梦梦, 陈秀秀, 王占坤, 董紫薇. 不同护肝药物护佑抗痨治疗防治药物性肝损伤发生研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 384-387.
[13]	卫栋萍, 韩黎黎, 凌佳慧, 顾晓琴, 曹永峰. 甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 388-391.
[14]	王焱, 周静, 韩军. 自身免疫性肝炎和药物性肝损伤患者临床病理特征分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 218-221.
[15]	徐菁, 刘坤, 马竹芳. 异甘草酸镁防治接受化疗的晚期胃癌患者肝肾功能损伤临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 234-237.